Using Antibodies to Activate Cancer Prodrugs
Author Information
Author(s): H.J. Haisma, E. Boven, M. van Muijen, J. de Jong, W.J.F. van der Vijgh, H.M. Pinedo
Primary Institution: Free University Hospital
Hypothesis
The prodrug Epi-glu would be less toxic than Epi, but upon hydrolysis, would be as active as Epi.
Conclusion
The study demonstrated that the 323/A3-GUS conjugate can specifically activate the stable non-toxic prodrug Epi-glu at the tumor cell level.
Supporting Evidence
- Epi-glu was found to be 100-1,000 times less toxic than Epi.
- Binding to target cells revealed an immunoreactivity of at least 60%.
- Complete activation of Epi-glu occurred by the 323/A3-GUS conjugate bound to tumor cells.
Takeaway
Scientists are trying to use special antibodies to turn a harmless medicine into a strong cancer-fighting drug right where it's needed.
Methodology
The study involved using a monoclonal antibody linked to an enzyme to activate a prodrug specifically at tumor sites.
Limitations
The study's findings may not yet be applicable in clinical settings due to issues with enzyme stability and uptake in human tissues.
Participant Demographics
Six female BALB/c mice were used for in vivo studies.
Want to read the original?
Access the complete publication on the publisher's website